Novel Treatments for TTR Amyloidosis | JACC Journal Club

In this JACC Journal Club session, we explore groundbreaking research on novel therapies for transthyretin (TTR) amyloidosis featuring Drs. Matthew Maurer and Michelle Kittleson. Learn how acoramidis and vutrisiran impact survival, how biomarkers like serum TTR/prealbumin guide therapy, and why early diagnosis is critical. This expert-led discussion offers clinical insights on managing ATTR-CM, optimizing treatment strategies, and improving patient access to care.

Related content:
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
https://www.jacc.org/doi/10.10....16/j.jacc.2025.03.54
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy
https://www.jacc.org/doi/10.10....16/j.jacc.2025.03.47

#JACCJournalClub
#jaccjournals
#ATTR
#Amyloidosis